These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12011306)

  • 1. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Richert ND
    Neurology; 2002 May; 58(9):1440-1; author reply 1441-2. PubMed ID: 12011306
    [No Abstract]   [Full Text] [Related]  

  • 2. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Filippi M; Rovaris M; Rocca MA; Sormani MP; Wolinsky JS; Comi G;
    Neurology; 2001 Aug; 57(4):731-3. PubMed ID: 11524494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.
    Sormani MP; Bruzzi P; Comi G; Filippi M
    Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
    Zivadinov R; Dwyer M; Barkay H; Steinerman JR; Knappertz V; Khan O
    J Neurol; 2015 Mar; 262(3):648-53. PubMed ID: 25542295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate.
    Cadavid D; Cheriyan J; Skurnick J; Lincoln JA; Wolansky LJ; Cook SD
    J Neurol Neurosurg Psychiatry; 2009 Dec; 80(12):1337-43. PubMed ID: 19687024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 8. Extended use of glatiramer acetate (Copaxone) for MS.
    Greenstein JI
    Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765
    [No Abstract]   [Full Text] [Related]  

  • 9. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
    Confavreux C; Vukusic S
    Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of magnetic resonance imaging studies in multiple sclerosis.
    Cerreta E
    J Neurosci Nurs; 1998 Oct; 30(5):290-301. PubMed ID: 9816560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
    Ziemssen T; Neuhaus O; Hohlfeld R
    Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost of delaying treatment in multiple sclerosis: what is lost is not regained.
    Zwibel H
    Neurology; 2002 Feb; 58(4):667; author reply 668. PubMed ID: 11865160
    [No Abstract]   [Full Text] [Related]  

  • 13. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis.
    Sormani MP; Rovaris M; Valsasina P; Wolinsky JS; Comi G; Filippi M
    Neurology; 2004 Apr; 62(8):1432-4. PubMed ID: 15111692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).
    Losy J; Michałowska-Wender G; Kurdyńska A; Wender M
    Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetization transfer imaging of acute black holes in patients on glatiramer acetate.
    Zivadinov R; Hussein S; Bergsland N; Minagar A; Dwyer MG
    Front Biosci (Elite Ed); 2012 Jan; 4(4):1496-504. PubMed ID: 22201970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current approved options for treating patients with multiple sclerosis.
    Rizvi SA; Agius MA
    Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)].
    Iakushina TI; Lizhdvoĭ VIu; Vasilenko IA; Andriukhina OM; Kotov SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):61-5. PubMed ID: 23528596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Time is brain' also in multiple sclerosis.
    Freedman MS
    Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.